GH Responsiveness to Combined GH-Releasing Hormone and Arginine Administration in Obese Patients with Fibromyalgia Syndrome
Table 1
Demographic, clinical, and hormonal characteristics of the obese women with fibromyalgia syndrome included in the study.
Parameter
All data
IGF-1 SDS > −2
IGF-1 SDS < −2
Number
16
12
4
Age (yrs)
36.5 ± 10.4
36.5 ± 10.5
36.8 ± 11.8
BMI (kg/m2)
43.6 ± 6.2
41.8 ± 4.2
48.9 ± 8.8
Waist (cm)
126.4 ± 11.1
123.9 ± 9.9
134.0 ± 12.6
Hip (cm)
133.8 ± 13.1
131.1 ± 6.4
141.8 ± 24.5
Fat mass (kg)
61.6 ± 12.9
58.6 ± 8.2
70.6 ± 19.8
Fat mass (%)
54.1 ± 4.7
53.0 ± 4.4
57.2 ± 4.6
Fat-free mass (kg)
51.6 ± 4.2
51.5 ± 3.6
51.7 ± 6.3
Fat-free nass (%)
46.0 ± 4.7
47.0 ± 4.4
42.8 ± 4.6
Tender-point score
14.7 ± 1.6
14.5 ± 1.5
15.3 ± 1.9
ESR (mm/h)
33.9 ± 18.7
34.8 ± 19.5
31.5 ± 18.7
CRP (mg/dl)
1.2 ± 1.2
0.9 ± 0.8
2.1 ± 2.1
IGF-1 (ng/ml)
138.1 ± 71.0
160.7 ± 66.2
70.5 ± 31.2
IGF-1 SDS
−1.1 ± 0.9
−0.7 ± 0.7
−2.3 ± 0.1
Peak GH (ng/ml)
10.4 ± 5.2
11.7 ± 5.0
6.7 ± 4.5
GH AUC (ng × min/ml)
716.7 ± 392.4
812.8 ± 391.4
428.3 ± 245.6
versus group with IGF-1 SDS > −2. BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IGF-1: insulin-like growth factor 1; GH: growth hormone; AUC: area under the curve.
